filibuvir: Clinical Trials

7 completed, 1 terminated. 6 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	6	Completed 5, Terminated 1
Phase 2	2	Completed 2

Follow filibuvir: new trials by email Literature Review of filibuvir trials Research Report on filibuvir

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance filibuvir - Chronic Hepatitis C	Phase 1	Completed	Pfizer	12	2011-02-01	2011-06-07
Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol) filibuvir + Oral Contraceptives - Hepatitis C	Phase 1	Completed	Pfizer	14	2010-06-01	2011-04-19
Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects Filibuvir, Placebo - Hepatitis, Hepatitis C	Phase 2	Completed	Pfizer	288	2009-11-01	2014-01-27
A Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 In Japanese Healthy Adult Volunteers PF-00868554 or Placebo - Healthy Volunteers	Phase 1	Terminated	Pfizer	24	2009-04-01	2009-10-22
A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection PF-00868554, Placebo - Hepatitis C	Phase 2	Completed	Pfizer	35	2008-08-01	2013-08-26
Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus. Small Molecule Agent (PF-868554) - Hepatitis, Chronic, Hepatitis C Virus	Phase 1	Completed	Pfizer	20	2008-04-01	2014-01-14
Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554 PF-868554 - HEPATITIS C (HCV)	Phase 1	Completed	Pfizer	24	2008-02-01	2014-01-03
A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients PF-00868554, Placebo - Hepatitis C	Phase 1	Completed	Pfizer	32	2007-01-01	2014-02-17

Conditions studied

Hepatitis C (6)  ·  Hepatitis (1)  ·  Hepatitis C, Chronic (1)  ·  Hepatitis, Chronic (1)

Sponsors

Pfizer (8)

Countries

United States (6)  ·  Belgium (3)  ·  Germany (2)  ·  Puerto Rico (2)  ·  Canada (1)  ·  France (1)  ·  Hungary (1)  ·  South Korea (1)  ·  Spain (1)  ·  United Kingdom (1)

Results publications

PMID 21488067, PMID 24927607